Prevention and treatment of gout
- PMID: 30546062
- DOI: 10.1038/s41584-018-0149-7
Prevention and treatment of gout
Similar articles
-
Recurrent Gout and Serum Urate.JAMA. 2024 May 28;331(20):1767. doi: 10.1001/jama.2024.5713. JAMA. 2024. PMID: 38696185 No abstract available.
-
A rare presentation of a first gout flare.Rheumatology (Oxford). 2023 Mar 1;62(3):e47. doi: 10.1093/rheumatology/keac425. Rheumatology (Oxford). 2023. PMID: 35881700 No abstract available.
-
Gout Flare and Cardiovascular Events.JAMA. 2023 Jan 3;329(1):96. doi: 10.1001/jama.2022.20111. JAMA. 2023. PMID: 36594952 No abstract available.
-
How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.Semin Arthritis Rheum. 2020 Apr;50(2):303-313. doi: 10.1016/j.semarthrit.2019.11.002. Epub 2019 Nov 11. Semin Arthritis Rheum. 2020. PMID: 31796212
-
Gout.Clin Evid. 2006 Jun;(15):1561-9. Clin Evid. 2006. PMID: 16973059 Review. No abstract available.
Cited by
-
Identification of Anastatica hierochuntica L. Methanolic-Leaf-Extract-Derived Metabolites Exhibiting Xanthine Oxidase Inhibitory Activities: In Vitro and In Silico Approaches.Metabolites. 2024 Jun 28;14(7):368. doi: 10.3390/metabo14070368. Metabolites. 2024. PMID: 39057691 Free PMC article.
-
Causal impact of human blood metabolites and metabolic pathways on serum uric acid and gout: a mendelian randomization study.Front Endocrinol (Lausanne). 2024 Jul 4;15:1378645. doi: 10.3389/fendo.2024.1378645. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39027467 Free PMC article.
-
NFIL3 Facilitates Neutrophil Autophagy, Neutrophil Extracellular Trap Formation and Inflammation During Gout via REDD1-Dependent mTOR Inactivation.Front Med (Lausanne). 2021 Sep 30;8:692781. doi: 10.3389/fmed.2021.692781. eCollection 2021. Front Med (Lausanne). 2021. Retraction in: Front Med (Lausanne). 2023 Mar 29;10:1187721. doi: 10.3389/fmed.2023.1187721. PMID: 34660620 Free PMC article. Retracted.
-
Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia.Front Pharmacol. 2021 Jul 14;12:667753. doi: 10.3389/fphar.2021.667753. eCollection 2021. Front Pharmacol. 2021. PMID: 34335246 Free PMC article.
-
Targeting Neutrophil Extracellular Traps in Gouty Arthritis: Insights into Pathogenesis and Therapeutic Potential.J Inflamm Res. 2024 Mar 19;17:1735-1763. doi: 10.2147/JIR.S460333. eCollection 2024. J Inflamm Res. 2024. PMID: 38523684 Free PMC article. Review.
References
-
- Rai, S. et al. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology 57, 1282–1292 (2018). - DOI
-
- Doherty, M. et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392, 1403–1412 (2018). - DOI
-
- White, W. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200–1210 (2018). - DOI
-
- Solomon, D. et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann. Intern. Med. 169, 535–542 (2018). - DOI
-
- Zhu, Y., Pandya, B. & Choi, H. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am. J. Med. 125, 679–687 (2012). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical